Your browser doesn't support javascript.
loading
Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.
de Mol van Otterloo, Sophie R; Christodouleas, John P; Blezer, Erwin L A; Akhiat, Hafid; Brown, Kevin; Choudhury, Ananya; Eggert, Dave; Erickson, Beth A; Daamen, Lois A; Faivre-Finn, Corinne; Fuller, Clifton D; Goldwein, Joel; Hafeez, Shaista; Hall, Emma; Harrington, Kevin J; van der Heide, Uulke A; Huddart, Robert A; Intven, Martijn P W; Kirby, Anna M; Lalondrelle, Susan; McCann, Claire; Minsky, Bruce D; Mook, Stella; Nowee, Marlies E; Oelfke, Uwe; Orrling, Kristina; Philippens, Marielle E P; Sahgal, Arjun; Schultz, Christopher J; Tersteeg, Robbert J H A; Tijssen, Rob H N; Tree, Alison C; van Triest, Baukelien; Tseng, Chia-Lin; Hall, William A; Verkooijen, Helena M.
Afiliação
  • de Mol van Otterloo SR; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Christodouleas JP; Elekta AB, Stockholm, Sweden.
  • Blezer ELA; Division of Imaging, University Medical Center Utrecht, Utrecht, Netherlands.
  • Akhiat H; Elekta AB, Stockholm, Sweden.
  • Brown K; Elekta AB, Stockholm, Sweden.
  • Choudhury A; The University of Manchester and The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
  • Eggert D; Elekta AB, Stockholm, Sweden.
  • Erickson BA; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Daamen LA; Division of Imaging, University Medical Center Utrecht, Utrecht, Netherlands.
  • Faivre-Finn C; The University of Manchester and The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
  • Fuller CD; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center Houston, Houston, Texas.
  • Goldwein J; Elekta AB, Stockholm, Sweden.
  • Hafeez S; The Royal Marsden NHS Foundation Trust and The Institute of Cancer, London, United Kingdom.
  • Hall E; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Harrington KJ; The Royal Marsden NHS Foundation Trust and The Institute of Cancer, London, United Kingdom.
  • van der Heide UA; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Huddart RA; The Royal Marsden NHS Foundation Trust and The Institute of Cancer, London, United Kingdom.
  • Intven MPW; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Kirby AM; The Royal Marsden NHS Foundation Trust and The Institute of Cancer, London, United Kingdom.
  • Lalondrelle S; The Royal Marsden NHS Foundation Trust and The Institute of Cancer, London, United Kingdom.
  • McCann C; Department of Radiation Oncology, Sunnybrook Health Sciences Centre/Odette Cancer Centre, Toronto, Ontario.
  • Minsky BD; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center Houston, Houston, Texas.
  • Mook S; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Nowee ME; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Oelfke U; The Royal Marsden NHS Foundation Trust and The Institute of Cancer, London, United Kingdom.
  • Orrling K; Lygature, Utrecht, Netherlands.
  • Philippens MEP; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Sahgal A; Department of Radiation Oncology, Sunnybrook Health Sciences Centre/Odette Cancer Centre, Toronto, Ontario.
  • Schultz CJ; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Tersteeg RJHA; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Tijssen RHN; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Tree AC; The Royal Marsden NHS Foundation Trust and The Institute of Cancer, London, United Kingdom.
  • van Triest B; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Tseng CL; Department of Radiation Oncology, Sunnybrook Health Sciences Centre/Odette Cancer Centre, Toronto, Ontario.
  • Hall WA; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Verkooijen HM; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands; Division of Imaging, University Medical Center Utrecht, Utrecht, Netherlands. Electronic address: H.M.Verkooijen@umcutrecht.nl.
Int J Radiat Oncol Biol Phys ; 111(4): 867-875, 2021 11 15.
Article em En | MEDLINE | ID: mdl-34265394
ABSTRACT

PURPOSE:

High-field magnetic resonance-linear accelerators (MR-Linacs), linear accelerators combined with a diagnostic magnetic resonance imaging (MRI) scanner and online adaptive workflow, potentially give rise to novel online anatomic and response adaptive radiation therapy paradigms. The first high-field (1.5T) MR-Linac received regulatory approval in late 2018, and little is known about clinical use, patient tolerability of daily high-field MRI, and toxicity of treatments. Herein we report the initial experience within the MOMENTUM Study (NCT04075305), a prospective international registry of the MR-Linac Consortium. METHODS AND MATERIALS Patients were included between February 2019 and October 2020 at 7 institutions in 4 countries. We used descriptive statistics to describe the patterns of care, tolerability (the percentage of patients discontinuing their course early), and safety (grade 3-5 Common Terminology Criteria for Adverse Events v.5 acute toxicity within 3 months after the end of treatment).

RESULTS:

A total 943 patients participated in the MOMENTUM Study, 702 of whom had complete baseline data at the time of this analysis. Patients were primarily male (79%) with a median age of 68 years (range, 22-93) and were treated for 39 different indications. The most frequent indications were prostate (40%), oligometastatic lymph node (17%), brain (12%), and rectal (10%) cancers. The median number of fractions was 5 (range, 1-35). Six patients discontinued MR-Linac treatments, but none due to an inability to tolerate repeated high-field MRI. Of the 415 patients with complete data on acute toxicity at 3-month follow-up, 18 (4%) patients experienced grade 3 acute toxicity related to radiation. No grade 4 or 5 acute toxicity related to radiation was observed.

CONCLUSIONS:

In the first 21 months of our study, patterns of care were diverse with respect to clinical utilization, body sites, and radiation prescriptions. No patient discontinued treatment due to inability to tolerate daily high-field MRI scans, and the acute radiation toxicity experience was encouraging.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aceleradores de Partículas / Planejamento da Radioterapia Assistida por Computador Tipo de estudo: Etiology_studies / Observational_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Int J Radiat Oncol Biol Phys Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aceleradores de Partículas / Planejamento da Radioterapia Assistida por Computador Tipo de estudo: Etiology_studies / Observational_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Int J Radiat Oncol Biol Phys Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda